secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0001816590-25-000094
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Pathways appoints Justin Gover to board; Dr. Linda McGoldrick to retire Oct 31
--------------------------------------------------------------------------------

- Justin Gover appointed as Class III director effective July 29, 2025; joins audit/risk and scientific committees.
- Gover receives initial option for 52,000 ordinary shares vesting over 3 years; annual retainer of $40,000 plus committee fees.
- Linda McGoldrick to retire from board effective October 31, 2025; no disagreement with company.
- Gover was founding CEO of GW Pharmaceuticals (sold to Jazz for $7B) and led Epidiolex development/commercialization.
- Currently also serves on Xenon Pharmaceuticals (XENE) board; brings 25+ years biopharma experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000181659025000094/0001816590-25-000094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000181659025000094/cmps-20250728.htm
  HTML page:      https://secwatch.observer/filing/0001816590-25-000094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer